Maarten Altelaar
I'm happy to share the first papers in our recently launched journal, Translational Proteomics, as we welcome in the New Year. Elsevier's strong backing and the passionate involvement of the Journal's Associate Editors and Editorial Board members have made this possible. Proteomics researchers and clinicians in academia and industry have grown increasingly frustrated with the challenges of translating fundamental proteomics discoveries to therapeutic applications over the years. The lack of communication between fundamental scientists and physicians who received their training using conceptions that are at odds with one another is one of the causes of this barrier. The latter demand quick actions on patients rather than total certainty, whilst the former desire to control and comprehend all aspects.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi